1
Thomas W Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P Bergstrom, Piyasena Hewawasam, Scott W Martin, Robert G Gentles: Inhibitors of HCV replication. Bristol Myers Squibb Company, James Epperson, Pamela A Mingo, December 26, 2006: US07153848 (54 worldwide citation)

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.


2
Thomas W Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P Bergstrom, Piyasena Hewawasam, Scott W Martin, Robert G Gentles: Inhibitors of HCV replication. Bristol Myers Squibb Company, James Epperson, Pamela A Mingo, March 25, 2008: US07348425 (36 worldwide citation)

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds


3
Michael F Parker, Katharin E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors. Bristol Myers Squibb Company, Aldo A Algieri, November 27, 2007: US07300936 (21 worldwide citation)

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


4
Carl P Bergstrom: Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors. Bristol Myers Squibb Company, James Epperson, November 25, 2008: US07456167 (11 worldwide citation)

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.


5
Carl P Bergstrom, Scott W Martin, Thomas W Hudyma: HCV NS5B inhibitors. Bristol Myers Squibb Company, James Epperson, November 25, 2008: US07456165 (9 worldwide citation)

The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.


6
Carl P Bergstrom, John A Bender, Robert G Gentles, Piyasena Hewawasam, Thomas W Hudyma, John F Kadow, Scott W Martin, Alicia Regueiro Ren, Kap Sun Yeung, Yong Tu, Katharine A Grant Young, Xiaofan Zheng: Indolobenzazepine HCV NS5B inhibitors. Bristol Myers Squibb Company, James Epperson, January 6, 2009: US07473688 (9 worldwide citation)

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.


7
Robert G Gentles, Piyasena Hewawasam, Min Ding, Carl P Bergstrom, Scott W Martin, Kap Sun Yeung, Thomas W Hudyma, Xiaofan Zheng, John A Bender, John F Kadow: Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors. Bristol Myers Squibb Company, James Epperson, April 21, 2009: US07521441 (8 worldwide citation)

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.


8
David W Smith, Benito Munoz, Kumar Srinivasan, Carl P Bergstrom, Prasad V Chaturvedula, Milind S Deshpande, Daniel J Keavy, Wai Yu Lau, Michael F Parker, Charles P Sloan, Owen B Wallace, Henry Hui Wang: Sulfonamide compounds and uses thereof. Bristol Myers Squibb Company, Merck & Co, Hoffmann & Baron, November 22, 2005: US06967196 (6 worldwide citation)

In accordance with the present invention, there is provided a novel class of sulfonamide compounds. Compounds of the invention contain a core sulfonamide group. Variable moieties connected to the sulfur atom and nitrogen atom of the sulfonamide group include substituted or unsubstituted hydrocarbyl ...


9
Michael F Parker, Katharine E McElhone, Robert A Mate, Joanne J Bronson, Yonghua Gai, Carl P Bergstrom, Lawrence R Marcin, John E Macor: α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors. Bristol Myers Squibb Company, Aldo A Algieri, Pamela A Mingo, August 31, 2010: US07786122 (5 worldwide citation)

There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid ac ...


10
Scott W Martin, Carl P Bergstrom, Robert G Gentles, Kap Sun Yeung: Compounds for the treatment of hepatitis C. Bristol Myers Squibb Company, James Epperson, January 26, 2010: US07652004 (3 worldwide citation)

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.



Click the thumbnails below to visualize the patent trend.